Cannabis Science, Inc. (PC) Stock Price - CBIS

Best deals to access real time data!
SMALL CAP BASIC
Monthly Subscription
for only
$29.03
SMALL CAP PRO
Monthly Subscription
for only
$43.59
Real-Time Alerts for Volume Breakouts, Highs and Lows for OTC Markets and OTCBB
Monthly Subscription
for only
$49.99
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Cannabis Science, Inc. (PC) CBIS Other OTC Common Stock Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  +0.00335 +9.36% 0.03915 0.0399 0.0359 0.0363 0.0358 15:21:55
Bid Price Ask Price Spread Spread % News
0.039 0.0393 0.0003 0.76% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,108.00 20,986,560.00 $ 0.04 $ 794.03k 44.43M 0.01 - 0.68
Last Trade Time Type Quantity Stock Price Currency
15:21:55 4,600.00 $0.04 USD

Cannabis Science, Inc. (PC) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
82086838.008 2.31B $ -18.62M - - 24M
Short Interest Short % of Out Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.66M 0.07% $ - 0.00% - -

more financials information »

Cannabis Science, Inc. (PC) News


Historical CBIS Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.03770.03990.0330.000010M31M18M0.003.85%
1 Month0.063250.06840.0271090.000010M107M44M-0.02-38.10%
3 Months0.01480.6750.012910.00003M198M47M0.02164.53%
6 Months0.016050.6750.011930.00001M198M26M0.02143.93%
1 Year0.016750.6750.01010.00001M198M20M0.02133.73%
3 Years0.0320.6750.01010.00000198M13M0.0122.34%
5 Years0.01250.6750.00010.00000198M11M0.03213.20%

Cannabis Science, Inc. (PC) Description

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.